Limited Benefit And High Cost Responsible For NICE's Decision On Lapatinib

[News]

Following extensive consultation with pharmaceutical companies, healthcare professionals, charities and patient groups, the National Institute for Health and Clinical Excellence (NICE) has today (10 June) issued draft guidance recommending lapatinib (Tyverb, GlaxoSmithKline), in combination with capecitabine (Xeloda), for women with advanced or metastatic HER2-positive breast c...

More...